Benzinga - by Avi Kapoor, Benzinga Staff Writer.
Shares of Aehr Test Systems (NASDAQ: AEHR) shares fell sharply in pre-market trading after the company lowered its full-year revenue guidance.
The company said revenue will likely be impacted by an anticipated delay in the timing of new orders from current and new customers.
Aehr Test Systems shares dipped 15% to $18.99 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers
- Exicure, Inc. (NASDAQ: XCUR) shares rose 35.5% to $0.84 in pre-market trading. Exicure was granted broad U.S. patent #11866700 for "Liposomal Nucleic Acid Constructs Presenting Antisense Oligonucleotides For Knockdown Of Interleukin 17 Mrna (For Inflammation From Cancer, Obesity, Diabetes, Alzheimer's)."
- iCoreConnect Inc. (NASDAQ: ICCT) shares rose 32.3% to $1.72 in pre-market trading. iCoreConnect announced strategic acquisition of Verifi Dental.
- Zoomcar Holdings, Inc. (NASDAQ: ZCAR) shares jumped 15.8% to $7.40 in pre-market trading after surging more than 60% on Tuesday.
- Microvast Holdings, Inc. (NASDAQ: MVST) shares gained 13.8% to $1.40 in pre-market trading after falling 5% on Tuesday.
- SMART Global Holdings Inc. (NASDAQ: SGH) gained 10.7% to $20.45 in pre-market trading after the company posted better-than-expected earnings for its first quarter and announced approval of $75 million share repurchase authorization.
- PriceSmart, Inc. (NASDAQ: PSMT) gained 10% to $80.20 in pre-market trading as the company reported better-than-expected earnings for its first quarter on Tuesday.
- TG Therapeutics, Inc. (NASDAQ: TGTX) surged 9.1% to $22.93 in pre-market trading. TG Therapeutics recently announced that it has entered into an agreement with Precision BioSciences to acquire a worldwide license to Precision's Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.
- Hanryu Holdings, Inc. (NASDAQ: HRYU) shares climbed 8.5% to $0.91 in pre-market trading after falling around 7% on Tuesday.
- Green Giant Inc. (NASDAQ: GGE) shares rose 7.6% to $0.0440 in pre-market trading after declining around 5% on Tuesday.
- Intuitive Surgical, Inc. (NASDAQ: ISRG) gained 5.3% to $348.01 in pre-market trading. Intuitive Surgical said it sees preliminary revenue of $1.93 billion for the fourth quarter, versus market estimates of $1.87 billion.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers- Roma Green Finance Limited (NASDAQ: ROMA) shares fell 29.3% to $2.05 in pre-market trading after dipping over 27% on Tuesday. Roma Green Finance announced pricing of $12.3 million public offering of 2,449,943 of shares at price of $4.00 per share.
- HWH International Inc. (NASDAQ: HWH) shares fell 16.3% to $2.36 in pre-market trading after dipping 26% on Tuesday.
- NexImmune, Inc. (NASDAQ: NEXI) shares fell 12.6% to $10.31 in pre-market trading after jumping over 55% on Tuesday.
- MicroCloud Hologram Inc. (NASDAQ: HOLO) fell 10.2% to $0.2672 in pre-market trading after gaining 22% on Tuesday.
- Elevation Oncology, Inc. (NASDAQ: ELEV) shares fell 8.1% to $1.81 in pre-market trading after gaining around 9% on Tuesday. Elevation Oncology recently said that it plans to provide an update from its ongoing Phase 1 trial of EO-3021 in mid-2024, with additional data expected in the first half of 2025.
- Galera Therapeutics, Inc. (NASDAQ: GRTX) shares fell 7.4% to $0.1952 in pre-market trading after jumping 41% on Tuesday.
- Wearable Devices Ltd. (NASDAQ: WLDS) fell 6.7% to $0.42 in pre-market trading.
- AERWINS Technologies Inc. (NASDAQ: AWIN) shares declined 6.5% to $0.1230 in pre-market trading. AERWINS Technologies recently entered into a letter of intent to form an entity with Helicopter Technology.
- Sasol Limited (NYSE: SSL) shares fell 4.7% to $9.28 in pre-market trading.
Now Read This: Citigroup Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.